Holen Sie sich die Stockscreener-App
4.5301
6.57%
0.2701
Schlusskurs vom Vortag:
$4.26
Offen:
$4.33
24-Stunden-Volumen:
56,908
Relative Volume:
0.48
Marktkapitalisierung:
$4.62M
Einnahmen:
$10.48M
Nettoeinkommen (Verlust:
$-37.74M
KGV:
-0.2799
EPS:
-16.1846
Netto-Cashflow:
$-29.03M
1W Leistung:
-17.45%
1M Leistung:
-25.57%
6M Leistung:
-82.54%
1J Leistung:
-97.64%
1-Tages-Spanne:
$4.2601
$4.65
1-Wochen-Bereich:
$4.11
$6.90
52-Wochen-Spanne:
$4.02
$181.20
Jaguar Health Inc Stock (JAGX) Company Profile
Firmenname
Jaguar Health Inc
Sektor
Branche
Telefon
415-371-8300
Adresse
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Vergleichen Sie JAGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
4.5301 | 4.16M | 10.48M | -37.74M | -29.03M | -16.18 |
|
ONC
Beigene Ltd Adr
|
238.71 | 23.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.72 | 108.15B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2548 | 43.44M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
595.19 | 61.69B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.50 | 5.72B | 0 | -153.72M | -103.81M | -2.00 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-07-11 | Eingeleitet | Rodman & Renshaw | Buy |
Jaguar Health Inc Aktie (JAGX) Neueste Nachrichten
Jaguar Health Announces $1.5M Direct Stock Offering - TipRanks
Jaguar Health $1.5M Stock Offering Sparks Retail Buzz; Traders Call It A ‘Dip Opportunity’ By Stocktwits - Investing.com India
Jaguar Health announces $1.5 million direct offering By Investing.com - Investing.com South Africa
Jaguar Health prices 0.25M shares at $6.09 in registered direct offering - MSN
Jaguar Health (JAGX) Announces Direct Offering and Private Placement | JAGX Stock News - GuruFocus
Jaguar Health Prices Offering of Shares, Warrants - marketscreener.com
Jaguar Health announces $1.5 million direct offering - Investing.com
Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | JAGX Stock News - GuruFocus
Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - ACCESS Newswire
Jaguar Health Secures Fresh Capital: $1.5M Direct Offering Plus WarrantsKey Terms Revealed - Stock Titan
SEC Form 424B5 filed by Jaguar Health Inc. - Quantisnow
Jaguar Health (JAGX) Advances Crofelemer Trial for Rare Pediatri - GuruFocus
First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID) | JAGX Sto - GuruFocus
First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID) - Yahoo Finance
JAGX: Jaguar Health Coverage Initiated with Buy Rating | JAGX Stock News - GuruFocus
Jaguar Health outlines rare disease catalyst convergence and expedited regulatory pathways for crofelemer following proof-of-concept results - MSN
Jaguar Health, Inc. (NASDAQ:JAGX) Q1 2025 Earnings Call Transcript - MSN
Jaguar Animal Health: Mixed Sentiments in Latest Earnings Call - TipRanks
Jaguar Health Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Jaguar Health Inc (JAGX) Q1 2025 Earnings Call Highlights: Navigating Challenges with Promising ... - Yahoo Finance
Jaguar Health Reports Q1 2025 Financial Results - TipRanks
Transcript : Jaguar Health, Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
Earnings call transcript: Jaguar Health reports Q1 2025 with stock drop - Investing.com India
Jaguar Animal Health Executes Stock Exchange Agreements - TipRanks
Jaguar Health Reports First Quarter 2025 Financials | JAGX Stock News - GuruFocus
JAGX Reports Decrease in Q1 2025 Product Revenue | JAGX Stock News - GuruFocus
Jaguar Health Reports First Quarter 2025 Financials - ACCESS Newswire
JAGXJaguar Health Inc Latest Stock News & Market Updates - Stock Titan
Jaguar Health, Inc. SEC 10-Q Report - TradingView
Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 - GuruFocus
Jaguar Health Earnings Tomorrow: Q1 2025 Results Plus Major Corporate Updates Coming - Stock Titan
Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates - Sacramento Bee
Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $5.7 Million - ACCESS Newswire
Jaguar Health Investor Webcast Rescheduled for Wednesday, November 17th at 8:30 AM Eastern Time - ACCESS Newswire
Jaguar Health (JAGX) to Release Quarterly Earnings on Tuesday - Defense World
Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs - The Globe and Mail
Jaguar Health Highlights Promising Crofelemer Study Results - TipRanks
Jaguar Health to Host Investor Webcast Monday, March 14th at 8:30 AM Eastern Time Regarding Q4 2021 Financials & Corporate Updates - ACCESS Newswire
Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, - PharmiWeb.com
Jaguar Health Celebrates National Pet Cancer Awareness Month: Wi - GuruFocus
Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs | JAGX Stock News - GuruFocus
Jaguar Health (JAGX) Advances Crofelemer for Rare Diseases and Breast Cancer | JAGX Stock News - GuruFocus
Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts | JAGX Stock News - GuruFocus
Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts - Yahoo Finance
Article About Jaguar Health Published in Fall 2019 Issue of MicroCap Review Magazine - ACCESS Newswire
Form S-8Securities to be offered to employees in employee benefit plans - ADVFN
Geode Capital Management LLC Has $98,000 Position in Jaguar Health, Inc. (NASDAQ:JAGX) - Defense World
Jaguar Health Announces Closing of $6.0 Million Issuance and Sale of Designation-backed Note Related to Possible Tropical Disease Priority Review Voucher - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Jaguar Health (JAGX) Reports Positive Trial Results for Crofelemer Formulation | JAGX Stock News - GuruFocus
Finanzdaten der Jaguar Health Inc-Aktie (JAGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.40%
8.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):